共 32 条
Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
被引:6
作者:
Behera, Sapan K.
[1
]
Das, Saibal
[1
]
Chengappa, Kavadichanda G.
[2
]
Xavier, Alphienes S.
[3
]
Selvarajan, Sandhiya
[1
]
机构:
[1] JIPMER, Dept Clin Pharmacol, Pondicherry 605006, India
[2] JIPMER, Dept Clin Immunol, Pondicherry, India
[3] Sri Ramachandra Inst Higher Educ & Res, Dept Pharmacol, Chennai, Tamil Nadu, India
来源:
CURRENT CLINICAL PHARMACOLOGY
|
2019年
/
14卷
/
02期
关键词:
Multiple drug intolerance syndrome;
antibiotics;
hypersensitivity;
immunological reactions;
floctafenine;
pyrazolones;
ASPIRIN CHALLENGE;
TOLERANCE-TEST;
ALLERGY;
DIAGNOSIS;
HISTORY;
SAFETY;
D O I:
10.2174/1574884713666181112125714
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Aim: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. Methods: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS. Results: The most common cause of MDIS is antibiotics followed by non-steroidal anti-inflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug rechallenges and desensitization may be required for the management of this syndrome. Conclusion: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization.
引用
收藏
页码:84 / 90
页数:7
相关论文